MetaCap

Syndax Pharmaceuticals (SNDX) vs Verastem (VSTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Verastem (VSTM) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 36.7% versus a loss of 50.0%. Over five years, SNDX leads with a -47.1% price change compared with -80.3% for VSTM. Verastem is the larger company by market cap ($797.7 million vs $785.0 million), about 1.0 times the size, while Syndax Pharmaceuticals is growing revenue faster (+627.8% vs +209.1%).

Syndax Pharmaceuticals converts more of its revenue into profit, with a net margin of -165.6% versus -677.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SNDX-50.00%VSTM-36.70%
+50%-11%-71%
Nov 21, 20251 yearNov 20, 2026
SNDX-50.90%VSTM-82.18%
+66%-18%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SNDX versus VSTM key metrics
MetricSNDXVSTM
Share price$8.72$6.33
Market cap$785.05M$797.67M
1-day change-4.49%-7.73%
YTD return-58.50%-18.01%
1-year return-50.00%-36.70%
5-year return-47.09%-80.32%
EPS (TTM)$-2.37$-1.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$172.35M$30.91M
Revenue growth (YoY)+627.84%+209.14%
Net income (latest FY)$-285.42M$-209.47M
Operating margin-158.45%-550.33%
Net margin-165.60%-677.59%
52-week high$25.59$10.82
52-week low$8.41$3.43
Distance from 52-week high-65.92%-41.50%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+306.54%+172.04%
Average volume2.63M3.53M
Shares outstanding90.03M126.01M
Employees298102
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VSTM has outperformed SNDX by 13.3 percentage points over the past year.
  • Syndax Pharmaceuticals is more profitable, keeping -165.6 cents of every revenue dollar as net income versus -677.6 cents for Verastem.
  • Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +209.14%).

About Syndax Pharmaceuticals

SNDX stock →

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees

About Verastem

VSTM stock →

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

SNDX vs VSTM FAQ

Which is bigger, Syndax Pharmaceuticals or Verastem?

Verastem (VSTM) is larger, with a market capitalization of $797.67M compared with $785.05M for Syndax Pharmaceuticals (SNDX).

Which stock has performed better over the past year, SNDX or VSTM?

VSTM returned -36.70% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.

Are Syndax Pharmaceuticals and Verastem in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons